Health Discovery Corporation (OTCBB: HDVY) (“HDC”), announced that two members of its senior management team will be speaking at the “Personalized Medicine Partnerships” conference taking place today in Philadelphia, PA. The conference is sponsored by Arrowhead Conferences, a business-to-business conference group based in Redlands, Calif. Stephen D. Barnhill, M.D., Chairman and CEO, and John A. Norris, J.D., M.B.A., COO, of Health Discovery Corporation, will make a presentation describing the value of partnerships in furtherance of personalized medicine. The Company has developed strong relationships with leading companies such as Quest Diagnostics Incorporated, and Abbott Laboratories to commercialize HDC’s non-invasive, four-gene test for clinically-significant prostate cancer, among other initiatives. Other presenters include representatives from Pfizer, AstraZeneca, Merck, J&J, Medco, Roche, PriceWaterhouseCoopers, LabCorp, Abbott, FDA, NCI, The European Commission, and The National Human Genome Institute. About Health Discovery Corporation Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscoverycorp.com. Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.
All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.